BioSpace News Archive

Appili Therapeutics Inc. has added several clinical research sites in Mexico and Brazil to its Phase 3 clinical trial evaluating Avigan®/Reeqonus™ (favipiravir) as a potential oral therapy for patients with mild-to-moderate COVID-19.

ContraFect Corporation, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced that Gary Woodnutt, Ph.D. has been appointed as Senior Vice President of Translational Sciences and Preclinical Development.

Caladrius Biosciences, Inc. today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius, will present at the Investor Forum at the World Stem Cell Summit to be held (virtually) June 14-18, 2021.